We have successfully completed a Good Clinical Practice (GCP) inspection within the Gulf Cooperation Council (GCC) framework through a full on-site inspection, further validating the robustness and transparency of our processes.
The GCC brings together six countries: Saudi Arabia Sultanate, United Arab Emirates Kingdom, Qatar, Kuwait, Bahrain Kingdom, and Oman — a fast-growing and strategically important region for innovative therapies.
We are among a limited number GCC-recognized bioequivalence (BE) centers. Together with our regular inspections by the US FDA and EMA, this further strengthens our international regulatory foundation and highlights the consistent quality of our clinical research standards.
With this solid international track record, we are well positioned to support partners in navigating complex approval pathways and bringing new treatments to patients across the Middle East and beyond.
We look forward to building new collaborations and continuing to advance global healthcare innovation.
Would you like to know more? Let us know.
